IntegriChain delivers the life science industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, managed services and expert advisors to power their operations and harness the value of their channel, patient and payer data.
View all products
To ensure you get the most out of your access and commercialization investment, IntegriChain provides a complete set of professional Advisory and Systems Integration Services designed to further your business and success.
Services overview
IntegriChain provides wide array of resources to help you navigate your journey to market access success.
Resources overview
We help all stakeholders in the life sciences industry drive access. We do this through our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts and pricing, gross-to-net, channel, and patient services – unlocking strategic payer, provider, pharmacy and patient access insights for our life sciences customers.
Learn more about our company
Keep in touch with IntegrChain through our news and frequent events.
View all news & events
Business Type
Top-10 pharmaceutical company
Functional Area
Contract Analysis and Administration
Challenge
The manufacturer felt that there was a disconnect between the contract negotiation business function and the contract analysis business function. The belief was that contract performance was not living up to the contract expectations determined at the onset of the agreement. The manufacturer requested that we help determine if its investment was optimized by applying our Rational Pricing methodology to its pricing process.
Business Challenges
Solution
We analyzed more than two years of data for two highly promoted brands from a combination of 16 strategic PBMs and/or HMOs within the managed care market. We were provided with internal data from the administrative systems, and we loaded it into our business tool. Our software identified any gaps and inconsistencies and then analyzed the data from a performance perspective.
Results
As a result of our gap analysis, we were able to identify non-performing and marginally performing investments that were not generating the expected ROI. We also assisted the manufacturer in profiling the accounts under review to determine an optimum and rational price for each account.
Key Takeaways